HC Wainwright Issues Pessimistic Estimate for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.09. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $0.81 EPS and FY2027 earnings at $1.25 EPS.

Separately, Craig Hallum lifted their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Price Performance

ETON opened at $12.74 on Wednesday. The business’s 50-day moving average is $8.23 and its two-hundred day moving average is $5.36. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $12.77. The firm has a market capitalization of $329.15 million, a PE ratio of -56.05 and a beta of 1.25.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently modified their holdings of the business. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the second quarter valued at approximately $3,095,000. Westside Investment Management Inc. boosted its position in Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after buying an additional 33,275 shares during the last quarter. Geode Capital Management LLC boosted its position in Eton Pharmaceuticals by 13.5% in the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in Eton Pharmaceuticals by 2.8% in the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after buying an additional 7,029 shares during the last quarter. Finally, Wasatch Advisors LP purchased a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $1,431,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. purchased 16,852 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were acquired at an average price of $6.77 per share, for a total transaction of $114,088.04. Following the completion of the purchase, the insider now owns 2,720,000 shares of the company’s stock, valued at approximately $18,414,400. The trade was a 0.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have acquired 85,600 shares of company stock worth $462,674. Insiders own 14.89% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.